ヘリオス（4593） – License Agreement with CellFiber Co., Ltd.

March 24, 2022 Company Name: Representative: HEALIOS K.K. Hardy TS Kagimoto, Chairman & CEO (TSE Mothers Code: 4593) License Agreement with CellFiber Co., Ltd. HEALIOS K.K. (“Healios”) announces that it has entered into a license agreement with CellFiber Co., Ltd. (Head office: Bunkyo-ku, Tokyo; Representative Directors: Yu Yanagisawa and Aki Adachi; hereinafter referred to as “CellFiber”), a startup company developing cell manufacturing technology utilizing CellFiber’s fiber based production system. By introducing CellFiber’s fiber technology, Healios aims to develop highly efficient and scalable cell culturing and mass manufacturing systems for certain cell-based products it is developing. Healios is engaged in research of new therapies derived from induced pluripotent stem cells (iPS cells) and along with this is developing cell culturing systems to produce large amounts of cells for therapeutic use. In the CellFiber technology, cells are enclosed and cultured in hollow hydrogel fibers as thin as hair, a technology which has the potential to contribute to improved manufacturing outcomes. Under the terms of the license agreement, Healios will make an upfront payment of 50 million yen (excluding tax) to CellFiber. When Healios receives an income stream through the use of the licensed technology in the future, it will make milestone and running royalty payments to CellFiber based on business progress. ■ Outline of the contract partner Name of the company: CellFiber Co., Ltd. Address: 216, South Research Building, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8485, Japan Representatives: Yu Yanagisawa and Aki Adachi Business: Development of cell mass culture solutions using cell fiber technology Capital: 66,650,000 yen Established: April 1, 2015 This agreement does not have a material impact on our consolidated financial results for the current fiscal year. We will promptly make an announcement on any matter that requires disclosure in the future. About CellFIber: CellFiber is a startup from the University of Tokyo, which was established in April 2015. “Contributing to the solution of global issues through manufacturing using cells”, we have our own cell culture platform technology. It can be used in various fields, however, at present, CellFiber is mainly developing a solution to contribute to the reduction of development costs and treatment costs in the field of regenerative medicine. We are developing a solution. For more information about the company, please see https://cellfiber.jp/en ) About Healios: Healios is Japan’s leading clinical stage biotechnology company harnessing the potential of stem cells for regenerative medicine. It aims to offer new therapies for patients suffering from diseases without 1 effective treatment options. Healios is a pioneer in the development of regenerative medicines in Japan, where it has established a proprietary, gene-edited “universal donor” induced pluripotent stem cell (iPSC) line to develop next generation regenerative treatments in immuno-oncology, ophthalmology, liver diseases, and other areas of severe unmet medical need. Healios’ lead iPSC-derived cell therapy candidate, HLCN061, is a next generation NK cell treatment for solid tumors that has been functionally enhanced through gene-editing. Its near-term pipeline includes the somatic stem cell product HLCM051, which is currently being evaluated in Japan in Phase 2/3 and Phase 2 trials in ischemic stroke and acute respiratory distress syndrome (ARDS), respectively. Healios was established in 2011 the Tokyo Stock Exchange since 2015 (TSE Mothers: 4593). and has been https://www.healios.co.jp/en . listed on Contact: Department of Corporate Communications, HEALIOS K.K. E-mail: ir@healios.jp 2